Personalized Cancer Therapy using Growth Hormone Receptor Antagonists

A next-generation cancer treatment system utilizing growth hormone receptor antagonists tailored to individual patient profiles, enhancing treatment efficacy and minimizing side effects.

The original patent disclosed a composition for treating cancer using a human growth hormone receptor antagonist. However, it lacked personalization, resulting in variable treatment outcomes. This new inventive concept addresses this limitation by introducing a system that identifies a patient's specific growth hormone receptor expression profile, selects a customized combination of antagonist and chemotherapeutic drug, and administers the tailored treatment.

The system comprises three primary components: (1) a means for identifying a patient's specific growth hormone receptor expression profile, (2) a means for selecting a customized combination of a human growth hormone receptor antagonist and a chemotherapeutic drug based on the identified profile, and (3) a means for administering the customized combination to the patient. The modified antagonist features a polyethylene glycol molecule with a maleimide group for conjugation to a free sulfhydryl group, ensuring targeted delivery. The system also includes a monitoring component to track the patient's growth hormone receptor expression levels over time, enabling adjustments to the treatment regimen.

The new claims introduce a paradigm shift in cancer treatment by integrating personalized medicine with growth hormone receptor antagonists. The inventive concept's novelty lies in its ability to tailor treatment to individual patient profiles, whereas the original patent's composition was a one-size-fits-all approach.

Alternative embodiments may include varying the type of chemotherapeutic drug, using different methods for identifying patient profiles, or incorporating additional biomarkers to further personalize treatment. Variations may also involve adapting the system for treating other diseases responsive to human growth hormone receptor antagonists.

This inventive concept has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, targeted therapies, and companion diagnostics. The market for cancer treatment is projected to grow significantly in the coming years, driven by an increasing need for effective and personalized treatments.